GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary Disease (COPD).
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01787097).
- 07 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.